Connect Biopharma Holdings Ltd.
We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. The estimated global market for AD was approximately $10.4 billion in 2020 and is expected to grow to $19.3 billion by 2025, a compound annual growth rate, or CAGR, of 13.2%.
(Note: Connect Biopharma upsized its IPO at pricing on March 18, 2021: 11.25 million shares, up from 9.4 million in the prospectus, were priced at $17 each – the high end of the deal’s $15-to-$17 range – to raise $191.25 million.)
|Address||Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, China 215400|
|Phone Number||+86 512 5357 7866.|
|View Prospectus:||Connect Biopharma Holdings Ltd.|
|Revenues||$-30.3 mil (last 12 months)|
|Net Income||$-119.4 mil (last 12 months)|
|Price range||$17.00 - $17.00|
|Est. $ Volume||$191.3 mil|
|Manager / Joint Managers||Jefferies/ SVB Leerink/ Piper Sandler/ CICC|
|Expected To Trade:||3/19/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|